Results 11 to 20 of about 756 (101)

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan

Arthritis Research & Therapy, 2023
Objectives To investigate the efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and factors contributing to glucocorticoid (GC) discontinuation.
Takashi Yamane, Akira Hashiramoto
doaj   +1 more source

Response to mepolizumab treatment is sustained across 4-weekly dosing periods

ERJ Open Research, 2020
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids,
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers, Steven Yancey   +8 more
doaj   +1 more source

Characteristics of new adult users of mepolizumab with asthma in the USA

BMJ Open Respiratory Research, 2021
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon, Ann Chen Wu, Emily Welch, Cheryl N McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S Brown, Melissa K Van Dyke   +11 more
doaj   +1 more source

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses

Respiratory Research, 2023
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye, Tanawin Nopsopon, Laura Cho, Matthew Moll, Scott T. Weiss   +4 more
doaj   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Heliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi, Masamitsu Eitoku, Akihito Yokoyama   +2 more
doaj   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Journal of Allergy and Clinical Immunology: Global
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids.
Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD   +14 more
doaj   +1 more source

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis, Georgia Giannakopoulou, Konstantinos Samitas, Eleftherios Zervas   +3 more
doaj   +1 more source

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

Farmacia Hospitalaria, 2019
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin
Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo   +4 more
doaj   +1 more source

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
doaj   +1 more source